AGIO Agios Pharmaceuticals, Inc. - Common Stock
Über Agios Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Agios Pharmaceuticals Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Die therapeutischen Schwerpunkte des Unternehmens sind Krebs und seltene genetische Stoffwechselstörungen, bei denen es sich um eine Gruppe von über 600 seltenen genetischen Erkrankungen handelt, die durch Mutationen oder Defekte einzelner Stoffwechselgene verursacht werden.
Mehr lesen
Agios Pharmaceuticals Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Die therapeutischen Schwerpunkte des Unternehmens sind Krebs und seltene genetische Stoffwechselstörungen, bei denen es sich um eine Gruppe von über 600 seltenen genetischen Erkrankungen handelt, die durch Mutationen oder Defekte einzelner Stoffwechselgene verursacht werden.
## Geschichte
Das Unternehmen wurde 2008 von Lewis Cantley, Tak Mak und Craig Thompson gegründet.
Die Forschung hat ergeben, dass das mutierte metabolische Gen IDH1 eine neuartige Enzymaktivität hat, die mit einem Onkogen übereinstimmt und veröffentlichte 2009 den Artikel in der Zeitschrift Nature.
2010 bestand eine Zusammenarbeit mit dem amerikanischen Pharmaunternehmen Celgene Corporation, um neuartige zellstoffwechselbezogene Therapien zu entwickeln. Zusammen mit Mitarbeitern von Memorial Sloan Kettering veröffentlichte Agios einen Aufsatz in der Zeitschrift Cancer Cell, das möglicherweise eine IDH-Mutation in einen ausgeprägten Mechanismus der akuten myeloischen Leukämie (AML)-Pathogenese impliziert.
2011 erfolgte eine Ausdehnung der Forschung auf seltene genetische Stoffwechselstörungen.
2012 war die Entdeckung der ersten potenten Inhibitoren der mutierten IDH, die Tumor 2-HG in vivo senken und Veröffentlichung der Ergebnisse in der Zeitschrift American Chemical Society Medicinal Chemistry Letters. Im gleichen Jahr wurde Klage gegen einen seiner Gründer, Craig Thompson, erhoben, dem vorgeworfen wurde, Thompson habe in der Forschung in Agios illegal vom Abramson Family Cancer Research Institute entnommene Forschungsergebnisse verwendet.
2013 erfolgte ein Börsengang an der amerikanischen Börse NASDAQ. Erste klinische Studie mit Enasidenib bei Patienten mit IDH2-mutierten hämatologischen Malignitäten. 2014 war die Zulassung von Enasidenib sowohl Fast Track als auch Orphan Drug durch die Food and Drug Administration (FDA). 2015 folgte die Zulassung von Ivosidenib sowohl Fast Track als auch Orphan Drug durch die FDA. 2016 war der Eintritt in eine globale Forschungskooperation mit Celgene mit Schwerpunkt metabolische Immunonkologie. 2017 erfolgte eine Zulassung der ersten Medikaments IGHIFA aus der Zusammenarbeit mit Celgene. 2019 war die Eröffnung des europäischen Hauptsitzes in Zug, Schweiz.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
AGIO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
AGIO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
AGIO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
- Starker Kauf 5 31,2%
- Kauf 7 43,8%
- Halten 4 25,0%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
8 Analysten · 2026-08-16Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-1.69 | $-1.70 | 0.01% |
| 31. März 2026 | $-1.69 | $-1.84 | 0.15% |
| 31. Dezember 2025 | $-1.86 | $-1.99 | 0.13% |
| 30. September 2025 | $-1.78 | $-1.94 | 0.16% |
| 30. Juni 2025 | $-1.93 | $-1.84 | -0.09% |
| 31. März 2025 | $-1.55 | $-1.82 | 0.27% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | — |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | — |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | — |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | — |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | — |
| GENB | — | — | — | — | — | — |
| DMRA | — | — | 38.3% | -17981.1% | -167.0% | — |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | — |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Cost of Revenue | $6M | $4M | $3M | $2M | $0 | $0 | $1M | $1M | $0 | $0 | · | · | |
| R&D Expense | $340M | $301M | $296M | $280M | $257M | $221M | $214M | $341M | $293M | $220M | $142M | $100M | |
| SG&A Expense | $180M | $157M | $120M | $122M | $121M | $115M | $102M | $114M | $71M | $51M | $36M | $19M | |
| Operating Expenses | $526M | $462M | $418M | $403M | $378M | $336M | $316M | $457M | $364M | $271M | $178M | $119M | |
| Operating Income | $-472M | $-426M | $-391M | $-389M | $-378M | $-336M | $-316M | $-362M | $-321M | $-201M | $-119M | $-54M | |
| Interest Income | · | · | · | $13M | $836.0K | $7M | $15M | $16M | $6M | $3M | $968.0K | $203.0K | |
| Other Non-op | $2M | $6M | $6M | $7M | $14M | $0 | $0 | · | · | · | · | · | |
| Pretax Income | $-414M | $718M | $-352M | $-232M | $-357M | $-329M | $-301M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Income Tax | $-1M | $44M | $0 | $0 | · | · | $0 | $0 | $0 | $0 | $0 | $-426.0K | |
| Net Income | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| Shares (Basic) | 57,972,004 | 56,807,415 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| Shares (Diluted) | 57,972,004 | 57,889,255 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| EBITDA | $-472M | $-426M | $-391M | $-389M | $-378M | $-316M | $-418M | $-362M | $-321M | $-201M | $-119M | $-54M |
Bilanz 22
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89M | $76M | $88M | $139M | $203M | $127M | $81M | $71M | $103M | $161M | $72M | $14M | |
| Short-term Investments | · | · | · | · | · | · | · | $515M | $321M | $381M | · | · | |
| Inventory | $33M | $28M | $19M | $8M | $0 | $15M | $7M | $869.0K | $0 | · | · | · | |
| Prepaid Expense | $44M | $40M | $35M | $39M | $40M | $16M | $24M | $17M | $18M | $10M | $9M | $5M | |
| Current Assets | $942M | $966M | $834M | $833M | $1.06B | $637M | $612M | $614M | $445M | $560M | $337M | $360M | |
| PP&E (Net) | $11M | $12M | $15M | $23M | $29M | $31M | $31M | $24M | $24M | $25M | $23M | $6M | |
| PP&E (Gross) | $71M | $68M | $68M | $73M | $74M | $72M | $64M | $50M | $44M | $39M | $31M | $12M | |
| Accum. Depreciation | $60M | $56M | $52M | $50M | $45M | $41M | $32M | $26M | $19M | $13M | $8M | $6M | |
| Other Non-current Assets | $4M | $5M | $4M | $4M | $3M | $0 | $0 | $238.0K | $891.0K | $2M | $611.0K | $590.0K | |
| Total Assets | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Accounts Payable | $18M | $17M | $10M | $19M | $17M | $18M | $22M | $18M | $23M | $17M | $15M | $11M | |
| Accrued Liabilities | $45M | $47M | $43M | $30M | $32M | $31M | $53M | $42M | $34M | $32M | $16M | $14M | |
| Current Liabilities | $82M | $81M | $68M | $63M | $60M | $94M | $93M | $94M | $95M | $88M | $53M | $61M | |
| Capital Leases | $22M | $40M | $57M | $72M | $86M | $97M | $106M | · | · | · | · | · | |
| Other Non-current Liabilities | $90.0K | $880.0K | $1M | $3M | $0 | · | · | · | · | · | · | · | |
| Total Liabilities | $104M | $122M | $126M | $138M | $146M | $453M | $250M | $171M | $239M | $261M | · | · | |
| Common Stock | · | · | · | · | $71.0K | $69.0K | $68.0K | $58.0K | $49.0K | $42.0K | $38.0K | $37.0K | |
| Retained Earnings | $-562M | $-149M | $-823M | $-471M | $-239M | $-1.84B | $-1.52B | $-1.10B | $-798M | $-483M | $-285M | $-167M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $0 | · | · | · | · | · | · | |
| Stockholders' Equity | $1.19B | $1.54B | $811M | $1.10B | $1.29B | $400M | $641M | $688M | $376M | $359M | $345M | $424M | |
| Liabilities + Equity | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Shares Outstanding | 58,448,592 | 73,372,696,000 | 72,161,489 | 71,256,118 | 70,550,631 | 69,293,920 | 68,401,105 | 58,218,653 | 48,826,153 | 42,220,444 | 37,696,502 | 37,100,513 |
Cashflow 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $8M | $7M | $6M | · | · | · | |
| Stock-based Comp | $53M | $43M | $45M | $49M | $54M | $62M | $58M | $73M | $48M | $42M | $32M | $12M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | · | · | · | $-40M | · | · | · | · | · | |
| Operating Cash Flow | $-373M | $-390M | $-296M | $-309M | $-407M | $-291M | $-371M | $-304M | $-285M | $39M | $-77M | $-59M | |
| CapEx | $4M | $2M | $999.0K | $5M | $6M | $14M | $12M | $7M | $5M | $10M | $20M | $2M | |
| Investing Cash Flow | $377M | $363M | $240M | $243M | $1.25B | $76M | $91M | $-274M | $-58M | $-119M | $128M | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | $0 | $334M | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | · | $334M | |
| Financing Cash Flow | $9M | $14M | $5M | $2M | $-766M | $262M | $290M | $546M | $285M | $170M | $6M | · | |
| Net Change in Cash | $13M | $-12M | $-51M | $-64M | $76M | $47M | $10M | $-32M | $-58M | $89M | $58M | $-58M | |
| Taxes Paid | $628.0K | $43M | $2M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-377M | $-392M | $-297M | $-314M | $-413M | $-306M | $-383M | $-311M | $-290M | $29M | $-97M | $-62M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -361.6% | · | -745.8% | · | · | -82.8% | |
| Net Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | · | -161.1% | -349.0% | · | -731.6% | · | · | -81.9% | |
| Pretax Margin | -765.9% | 1967.2% | -1312.6% | -1627.8% | · | -161.2% | -349.0% | · | -731.6% | · | · | -82.5% | |
| EBITDA Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -354.7% | · | -745.8% | · | · | -82.8% | |
| ROA | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% | -25.8% | -15.4% | |
| ROE | -32.2% | 42.5% | -41.5% | -21.6% | 119.4% | -74.4% | -75.6% | -47.8% | -85.7% | -56.4% | -30.6% | -19.2% | |
| ROIC | -39.5% | -25.9% | · | · | · | · | -66.6% | -52.7% | -85.4% | · | · | -12.7% |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 | 6.7 | 6.6 | 6.6 | 4.7 | 6.3 | 6.4 | 5.9 | |
| Quick Ratio | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 | 1.4 | 0.9 | 6.3 | 4.5 | 1.8 | 1.4 | 0.2 |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.1 | · | 0.1 | · | · | 0.2 | |
| Inventory Turnover | 0.2 | 0.2 | 0.2 | 0.4 | · | 0.3 | 0.3 | 3.2 | · | · | · | · |
Wachstumsraten 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 48.0% | 36.1% | 88.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 56.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -24.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -25.1% | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Net Income TTM | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Market Cap | $1.59B | $1.88B | $1.25B | $1.55B | $1.79B | $3.00B | $3.27B | $2.68B | $2.79B | $1.76B | $2.45B | $4.16B | |
| P/E | -3.8 | 2.8 | -3.5 | -6.6 | 1.2 | -9.1 | -7.0 | · | · | · | · | -70.5 | |
| P/S | 29.4 | 51.5 | 46.4 | 108.5 | · | · | 27.7 | 28.4 | 64.9 | 25.2 | 41.4 | 63.6 | |
| P/B | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | 5.1 | 3.9 | 7.4 | 4.9 | 7.1 | 9.8 | |
| P / Tangible Book | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.3 | -4.8 | -4.2 | -5.0 | -4.4 | -10.3 | -8.8 | -8.8 | -9.8 | 45.7 | -31.8 | -70.0 | |
| P / FCF | -4.2 | -4.8 | -4.2 | -4.9 | -4.3 | -9.8 | -8.5 | -8.6 | -9.6 | 61.5 | -25.2 | -67.5 | |
| Earnings Yield | -26.2% | 35.4% | -28.4% | -15.1% | 80.8% | -10.9% | -14.4% | · | · | · | · | -1.4% |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $21M | $20M | $13M | $12M | $9M | $11M | $9M | $9M | $8M | $7M | $7M | $7M | $6M | $4M | $4M | |
| Cost of Revenue | $3M | $1M | $2M | $2M | $2M | $1M | $1M | $783.0K | $1M | $627.0K | $586.0K | $633.0K | $1M | $554.0K | $413.0K | $517.0K | |
| R&D Expense | $101M | $81M | $88M | $87M | $92M | $73M | $83M | $72M | $77M | $69M | $77M | $82M | $69M | $67M | $70M | $65M | |
| SG&A Expense | $52M | $48M | $52M | $41M | $46M | $42M | $52M | $39M | $36M | $31M | $35M | $26M | $30M | $28M | $33M | $29M | |
| Operating Expenses | $155M | $131M | $142M | $130M | $140M | $115M | $136M | $112M | $114M | $100M | $113M | $108M | $100M | $96M | $103M | $95M | |
| Operating Income | $-111M | $-110M | $-122M | $-117M | $-127M | $-107M | $-125M | $-103M | $-106M | $-92M | $-106M | $-101M | $-94M | $-91M | $-99M | $-91M | |
| Other Non-op | $119.0K | $119.0K | $113.0K | $67.0K | $523.0K | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | |
| Pretax Income | · | · | $-109M | $-103M | · | · | $-105M | $1.00B | · | · | $-96M | $-91M | · | · | · | · | |
| Income Tax | · | · | $-1M | $0 | · | · | $-9M | $53M | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Income | $-101M | $-99M | $-108M | $-103M | $-112M | $-89M | $-97M | $948M | $-96M | $-82M | $-96M | $-91M | $-84M | $-81M | $37M | $-82M | |
| EPS (Basic) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.65 | $16.65 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| EPS (Diluted) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.44 | $16.22 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| Shares (Basic) | 59,488,871 | 58,782,241 | -115,559,044 | 58,139,277 | 57,932,576 | 57,459,195 | -113,318,009 | 56,939,403 | 56,802,546 | 56,383,475 | -111,021,896 | 55,803,663 | 55,604,330 | 55,265,390 | -109,410,291 | 54,844,579 | |
| Shares (Diluted) | 59,488,871 | 58,782,241 | -115,559,044 | 58,139,277 | 57,932,576 | 57,459,195 | -113,729,562 | 58,432,796 | 56,802,546 | 56,383,475 | -111,021,896 | 55,803,663 | 55,604,330 | 55,265,390 | -109,410,291 | 54,844,579 | |
| EBITDA | $-111M | $-110M | · | $-117M | $-127M | $-107M | · | $-103M | $-106M | $-92M | · | $-101M | $-94M | $-91M | · | $-91M |
Bilanz 20
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $100M | $114M | $89M | $93M | $81M | $79M | $76M | $254M | $85M | $119M | · | $64M | $85M | $104M | · | $122M | |
| Inventory | $36M | $35M | $33M | $32M | $31M | $30M | $28M | $26M | $24M | $23M | · | $17M | $16M | $11M | · | $5M | |
| Prepaid Expense | $46M | $47M | $44M | $43M | $45M | $42M | $40M | $40M | $35M | $39M | · | $38M | $37M | $39M | · | $46M | |
| Current Assets | $718M | $835M | $942M | $1.03B | $1.02B | $969M | $966M | $1.07B | $632M | $664M | · | $704M | $757M | $792M | · | $785M | |
| PP&E (Net) | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $14M | · | $17M | $20M | $21M | · | $25M | |
| PP&E (Gross) | · | · | $71M | · | · | · | $68M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $60M | · | · | · | $56M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $10M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | · | $4M | $4M | $4M | · | $4M | |
| Total Assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Accounts Payable | $16M | $14M | $18M | $20M | $18M | $14M | $17M | $17M | $10M | $11M | · | $13M | $12M | $9M | · | $10M | |
| Accrued Liabilities | $35M | $26M | $45M | $37M | $35M | $21M | $47M | $33M | $37M | $25M | · | $30M | $29M | $22M | · | $30M | |
| Current Liabilities | $70M | $59M | $82M | $75M | $70M | $52M | $81M | $119M | $63M | $52M | · | $58M | $55M | $45M | · | $54M | |
| Capital Leases | $12M | $17M | $22M | $27M | $31M | $36M | $40M | $45M | $49M | $53M | · | $61M | $65M | $68M | · | $75M | |
| Other Non-current Liabilities | $240.0K | $90.0K | $90.0K | $90.0K | $101.0K | $880.0K | $880.0K | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $82M | $76M | $104M | $101M | $102M | $89M | $122M | $165M | $113M | $106M | · | $120M | $121M | $115M | · | $130M | |
| Retained Earnings | $-762M | $-661M | $-562M | $-454M | $-350M | $-238M | $-149M | $-52M | $-1.00B | $-904M | · | $-727M | $-635M | $-552M | · | $-507M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | · | $802M | $802M | $802M | · | $802M | |
| Stockholders' Equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B | $661M | $744M | $811M | $887M | $964M | $1.04B | $1.10B | $1.05B | |
| Liabilities + Equity | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Shares Outstanding | 59,604,830 | 59,341,338 | 58,448,592 | 58,279,876 | 58,038,545 | 57,886,781 | 57,156,285 | 57,021,543 | 56,875,079 | 56,751,511 | 72,161,489 | 55,883,973 | 55,734,775 | 55,541,367 | 71,256,118 | 54,894,031 |
Cashflow 9
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $16M | $16M | $14M | $12M | $15M | $11M | $11M | $11M | $12M | $9M | $14M | $9M | $12M | $10M | $11M | $11M | |
| Operating Cash Flow | $-57M | $-119M | $-96M | $-88M | $-77M | $-111M | $-133M | $-84M | $-73M | $-100M | $-72M | $-62M | $-67M | $-95M | $-66M | $-71M | |
| CapEx | $1M | $769.0K | $1M | $2M | $875.0K | $766.0K | $967.0K | $419.0K | $158.0K | $141.0K | $234.0K | $369.0K | $-3.0K | $399.0K | $113.0K | $38.0K | |
| Investing Cash Flow | $40M | $141M | $90M | $96M | $79M | $113M | $-49M | $251M | $37M | $125M | $96M | $39M | $47M | $58M | $83M | $104M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Financing Cash Flow | $3M | $2M | $3M | $4M | $65.0K | $2M | $5M | $3M | $1M | $6M | $847.0K | $2M | $237.0K | $2M | $22.0K | $1M | |
| Net Change in Cash | $-14M | $24M | $-4M | $12M | $2M | $3M | $-177M | $169M | $-34M | $31M | $24M | $-20M | $-19M | $-35M | $17M | $34M | |
| Taxes Paid | $70.0K | $4.0K | $-940.0K | $65.0K | $1M | $188.0K | $44M | $-34.0K | $-78.0K | $-525.0K | $-17.0K | $785.0K | $801.0K | $0 | · | $98.0K | |
| Free Cash Flow | · | $-120M | · | · | · | $-112M | · | · | · | $-100M | · | · | · | $-96M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| Net Margin | -225.1% | -477.7% | · | -803.0% | -899.4% | -1023.2% | · | 10574.7% | -1115.7% | -995.8% | · | -1234.3% | -1248.6% | -1444.4% | · | -2325.0% | |
| Pretax Margin | · | · | · | -803.0% | · | · | · | 11167.3% | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| ROA | -7.8% | -7.2% | · | -6.5% | -10.0% | -7.4% | · | 67.7% | -10.3% | -8.2% | · | -8.3% | -7.2% | -6.5% | · | -6.0% | |
| ROE | -8.4% | -7.7% | · | -7.1% | -11.0% | -8.1% | · | 75.4% | -11.8% | -9.2% | · | -9.4% | -8.0% | -7.2% | · | -6.7% | |
| ROIC | · | · | · | -9.1% | · | · | · | -6.0% | · | · | · | · | · | · | · | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.2 | 14.2 | · | 13.8 | 14.5 | 18.5 | · | 9.0 | 10.1 | 12.8 | · | 12.1 | 13.7 | 17.5 | · | 14.6 | |
| Quick Ratio | 1.4 | 1.9 | · | 1.2 | 1.1 | 1.5 | · | 2.1 | 1.3 | 2.3 | · | 1.1 | 1.5 | 2.3 | · | 2.3 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $91M | $55M | · | $43M | $39M | $34M | · | $33M | $31M | $28M | · | $23M | $21M | $16M | · | $10M | |
| Net Income TTM | $-415M | $-404M | · | $643M | $650M | $681M | · | $679M | $-353M | $-338M | · | $-338M | $-338M | $-349M | · | $-357M | |
| Market Cap | $2.21B | $2.01B | · | $2.34B | $1.93B | $1.70B | · | $2.53B | $2.45B | $1.66B | · | $1.38B | $1.58B | $1.28B | · | $1.55B | |
| P/E | -5.2 | -4.9 | · | 3.7 | 3.0 | 2.5 | · | 3.9 | -6.9 | -4.8 | · | -4.1 | -4.6 | -3.6 | · | -4.3 | |
| P/S | 24.4 | 36.6 | · | 54.4 | 49.8 | 49.2 | · | 76.4 | 79.3 | 59.5 | · | 59.5 | 73.7 | 82.1 | · | 156.3 | |
| P/B | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Tangible Book | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Cash Flow | · | -16.9 | · | · | · | -15.2 | · | · | · | -16.6 | · | · | · | -13.4 | · | · | |
| P / FCF | · | -16.8 | · | · | · | -15.1 | · | · | · | -16.6 | · | · | · | -13.3 | · | · | |
| Earnings Yield | -19.1% | -20.5% | · | 27.3% | 33.2% | 39.4% | · | 25.8% | -14.6% | -20.8% | · | -24.7% | -21.7% | -27.8% | · | -23.5% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $54M | $36M | $27M | $14M | $0 |
| Betriebsgewinnmarge % | -873.9% | -1166.5% | -1459.5% | -2732.1% | — |
| Nettoergebnis | $-413M | $674M | $-352M | $-232M | $1.60B |
| Verwässerte EPS | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 |
| Quick Ratio | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-377M | $-392M | $-297M | $-314M | $-413M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 264 Einreicher · $2.0B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 46 (+12 vs. Vorquartal) | 30 (-3 vs. Vorquartal) | 95 (+17 vs. Vorquartal) | 62 (-27 vs. Vorquartal) | +12.7M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $219.594.714 | 5.917.400 | 11,17% | Aktien |
| STATE STREET CORP | $131.144.972 | 3.533.633 | 6,67% | Aktien |
| Lynx1 Capital Management LP | $126.505.652 | 3.408.937 | 6,43% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107.552.091 | 2.898.197 | 5,47% | Aktien |
| ARMISTICE CAPITAL, LLC | $104.279.100 | 2.810.000 | 5,30% | Kaufoption |
| VANGUARD CAPITAL MANAGEMENT LLC | $99.523.268 | 2.681.845 | 5,06% | Aktien |
| ARMISTICE CAPITAL, LLC | $89.064.000 | 2.400.000 | 4,53% | Aktien |
| Erste Asset Management GmbH | $81.972.396 | 2.154.900 | 4,17% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $78.332.000 | 2.110.809 | 3,98% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $51.046.957 | 1.375.558 | 2,60% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $50.151.466 | 1.351.093 | 2,55% | Aktien |
| ADAR1 Capital Management, LLC | $47.799.647 | 1.288.053 | 2,43% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $44.225.805 | 1.191.749 | 2,25% | Aktien |
| GOLDMAN SACHS GROUP INC | $36.642.971 | 987.415 | 1,86% | Aktien |
| D. E. Shaw & Co., Inc. | $34.087.168 | 918.544 | 1,73% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $30.078.768 | 810.530 | 1,53% | Aktien |
| Foresite Capital Management VI LLC | $29.131.350 | 785.000 | 1,48% | Aktien |
| CITADEL ADVISORS LLC | $26.154.683 | 704.788 | 1,33% | Aktien |
| Parkman Healthcare Partners LLC | $24.828.297 | 669.046 | 1,26% | Aktien |
| SCS Capital Management LLC | $22.742.864 | 612.850 | 1,16% | Aktien |
| Qube Research & Technologies Ltd | $22.178.346 | 597.638 | 1,13% | Aktien |
| Defilade Capital Management, L.P. | $20.293.529 | 546.848 | 1,03% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.969.930 | 538.128 | 1,02% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $19.905.062 | 536.380 | 1,01% | Aktien |
| Rock Springs Capital Management LP | $19.763.413 | 532.563 | 1,01% | Aktien |
| Schonfeld Strategic Advisors LLC | $19.300.279 | 520.083 | 0,98% | Aktien |
| Point72 Asset Management, L.P. | $18.790.426 | 506.344 | 0,96% | Aktien |
| JANE STREET GROUP, LLC | $18.280.312 | 492.598 | 0,93% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $14.690.661 | 395.868 | 0,75% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $13.876.579 | 373.931 | 0,71% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.850.565 | 373.230 | 0,70% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $13.342.901 | 359.550 | 0,68% | Aktien |
| Squarepoint Ops LLC | $11.917.431 | 321.138 | 0,61% | Aktien |
| JPMORGAN CHASE & CO | $11.853.074 | 309.008 | 0,60% | Aktien |
| Ensign Peak Advisors, Inc | $11.045.049 | 297.630 | 0,56% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $9.996.803 | 269.383 | 0,51% | Aktien |
| ALGERT GLOBAL LLC | $9.203.540 | 248.007 | 0,47% | Aktien |
| JANE STREET GROUP, LLC | $7.974.939 | 214.900 | 0,41% | Verkaufsoption |
| Palo Alto Investors LP | $7.926.733 | 213.601 | 0,40% | Aktien |
| Tetragon Partners GP Ltd | $7.629.037 | 205.579 | 0,39% | Aktien |
| AXA Investment Managers S.A. | $7.131.875 | 177.675 | 0,36% | Aktien |
| Cutter Capital Management, LP | $6.895.755 | 235.350 | 0,35% | Aktien |
| BlackRock, Inc. | $6.545.388 | 176.378 | 0,33% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6.334.677 | 170.700 | 0,32% | Kaufoption |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $6.306.139 | 169.931 | 0,32% | Aktien |
| FIRST TRUST ADVISORS LP | $6.144.933 | 165.587 | 0,31% | Aktien |
| Ishara Investments LP | $6.086.040 | 164.000 | 0,31% | Aktien |
| GROUP ONE TRADING LLC | $5.640.497 | 151.994 | 0,29% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $5.562.269 | 149.886 | 0,28% | Aktien |
| BANK OF AMERICA CORP /DE/ | $5.505.083 | 148.345 | 0,28% | Aktien |
| MARSHALL WACE, LLP | $5.150.868 | 138.800 | 0,26% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.080.359 | 136.900 | 0,26% | Verkaufsoption |
| AMERICAN CENTURY COMPANIES INC | $4.991.740 | 134.512 | 0,25% | Aktien |
| Man Group plc | $4.617.931 | 124.439 | 0,23% | Aktien |
| ArrowMark Colorado Holdings LLC | $4.368.367 | 117.714 | 0,22% | Aktien |
| Pictet Asset Management Holding SA | $4.247.606 | 111.861 | 0,22% | Aktien |
| Swiss National Bank | $4.143.703 | 111.660 | 0,21% | Aktien |
| CAPITAL FUND MANAGEMENT S.A. | $3.862.408 | 104.080 | 0,20% | Aktien |
| Assenagon Asset Management S.A. | $3.857.770 | 103.955 | 0,20% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $3.700.831 | 99.726 | 0,19% | Aktien |
| Knott David M Jr | $3.527.602 | 95.058 | 0,18% | Aktien |
| Trexquant Investment LP | $3.471.232 | 93.539 | 0,18% | Aktien |
| CITADEL ADVISORS LLC | $3.402.987 | 91.700 | 0,17% | Kaufoption |
| Jain Global LLC | $3.401.020 | 91.647 | 0,17% | Aktien |
| Caligan Partners LP | $3.339.900 | 90.000 | 0,17% | Kaufoption |
| CITADEL ADVISORS LLC | $3.295.368 | 88.800 | 0,17% | Verkaufsoption |
| CITIGROUP INC | $3.182.331 | 85.754 | 0,16% | Aktien |
| RHUMBLINE ADVISERS | $2.948.045 | 79.441 | 0,15% | Aktien |
| Bank of New York Mellon Corp | $2.916.846 | 78.600 | 0,15% | Aktien |
| Campbell & CO Investment Adviser LLC | $2.712.555 | 73.095 | 0,14% | Aktien |
| Exome Asset Management LLC | $2.616.255 | 70.500 | 0,13% | Aktien |
| Edgestream Partners, L.P. | $2.604.936 | 70.195 | 0,13% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $2.441.059 | 65.779 | 0,12% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.319.520 | 68.564 | 0,12% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.319.144 | 85.200 | 0,12% | Aktien |
| ALPS ADVISORS INC | $2.228.789 | 60.059 | 0,11% | Aktien |
| Seven Fleet Capital Management LP | $2.111.559 | 56.900 | 0,11% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $2.092.859 | 61.864 | 0,11% | Aktien |
| Rafferty Asset Management, LLC | $2.062.574 | 55.580 | 0,10% | Aktien |
| Engineers Gate Manager LP | $2.000.674 | 53.912 | 0,10% | Aktien |
| WELLS FARGO & COMPANY/MN | $1.935.843 | 52.165 | 0,10% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.931.576 | 52.050 | 0,10% | Aktien |
| XTX Topco Ltd | $1.869.082 | 50.366 | 0,10% | Aktien |
| Caption Management, LLC | $1.855.500 | 50.000 | 0,09% | Kaufoption |
| Tetragon Partners GP Ltd | $1.855.500 | 50.000 | 0,09% | Kaufoption |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1.846.742 | 49.764 | 0,09% | Aktien |
| BARCLAYS PLC | $1.725.651 | 46.501 | 0,09% | Aktien |
| Quantinno Capital Management LP | $1.614.805 | 43.514 | 0,08% | Aktien |
| MARTINGALE ASSET MANAGEMENT L P | $1.596.064 | 43.009 | 0,08% | Aktien |
| IEQ CAPITAL, LLC | $1.499.392 | 40.404 | 0,08% | Aktien |
| Kodai Capital Management LP | $1.485.276 | 50.692 | 0,08% | Aktien |
| Virtus Investment Advisers, LLC | $1.464.843 | 39.473 | 0,07% | Aktien |
| Caption Management, LLC | $1.456.530 | 39.249 | 0,07% | Aktien |
| JANE STREET GROUP, LLC | $1.451.001 | 39.100 | 0,07% | Kaufoption |
| FMR LLC | $1.446.325 | 38.974 | 0,07% | Aktien |
| Aquatic Capital Management LLC | $1.433.448 | 38.627 | 0,07% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $1.400.049 | 37.727 | 0,07% | Aktien |
| VANGUARD GROUP INC | $1.308.928 | 48.087 | 0,07% | Aktien |
| EDGEWOOD MANAGEMENT LLC | $1.298.850 | 35.000 | 0,07% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.298.776 | 34.998 | 0,07% | Aktien |
Unternehmensinsider 33 Insider · 12 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Brian Goff | Chief Executive Officer | 18. Juni 2026 A | — | 0 | 0 | $0 |
| Cecilia Jones | Chief Financial Officer | 18. Juni 2026 A | — | 0 | 0 | $0 |
| Andrew Hirsch | Chief Financial Officer | 22. April 2019 A | 12.374 | 0 | 0 | $0 |
| John Duncan Higgons | Chief Operating Officer | 4. Januar 2016 M | 120.834 | 0 | 0 | $0 |
| Krishnan Viswanadhan | Chief Strategy and Operations | 18. Juni 2026 A | — | 0 | 0 | $0 |
| Tsveta Milanova | Chief Commercial Officer | 18. Juni 2026 A | — | 0 | 0 | $0 |
| James William Burns | Chief Legal Officer | 18. Juni 2026 A | — | 0 | 0 | $0 |
| Scott Biller | Chief Scientific Officer | 5. April 2019 M | 26.511 | 0 | 0 | $0 |
| Christopher Bowden | Chief Medical Officer | 1. April 2019 M | 7.238 | 0 | 0 | $0 |
| Steven L. Hoerter | Chief Commercial Officer | 4. März 2019 M | 10.941 | 0 | 0 | $0 |
| Carman Alenson | Principal Accounting Officer | 22. Februar 2019 A | 2.796 | 0 | 0 | $0 |
| Glenn Goddard | Senior Vice President, Finance | 16. Februar 2016 A | 0 | 0 | 0 | $0 |
| Adams Catherine Owen | Direktor | 18. Juni 2026 A | 10.865 | 0 | 0 | $0 |
| Rahul D. Ballal | Direktor | 18. Juni 2026 A | 15.230 | 0 | 0 | $0 |
| David Scadden | Direktor | 18. Juni 2026 A | 20.419 | 0 | 0 | $0 |
| Maykin Ho | Direktor | 18. Juni 2026 A | 19.848 | 0 | 0 | $0 |
| Cynthia Smith | Direktor | 18. Juni 2026 A | 15.230 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Direktor | 18. Juni 2026 A | 154.156 | 0 | 0 | $0 |
| Kaye I Foster-Cheek | Direktor | 18. Juni 2026 A | 10.284 | 0 | 0 | $0 |
| Jeffrey D Capello | Direktor | 18. Juni 2026 A | 10.865 | 0 | 0 | $0 |
| Paul J Clancy | Direktor | 31. Mai 2019 M | 1.400 | 0 | 0 | $0 |
| Ian T Clark | Direktor | 31. Mai 2019 M | 1.400 | 0 | 0 | $0 |
| John Maraganore | Direktor | 31. Mai 2019 M | 37.609 | 0 | 0 | $0 |
| David P Schenkein | Direktor | 22. Februar 2019 A | 89.503 | 0 | 0 | $0 |
| Lewis Clayton Cantley Jr. | Direktor | 7. Dezember 2017 S | 79.515 | 0 | 0 | $0 |
| Robert Nelsen | Direktor | 6. März 2017 S | 0 | 0 | 0 | $0 |
| Douglas G. Cole | Direktor | 10. August 2016 J | 2.778 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Direktor | 21. Juni 2016 A | 101.009 | 0 | 0 | $0 |
| Perry A Karsen | Direktor | 23. Juni 2015 A | — | 0 | 0 | $0 |
| Kevin P Starr | Direktor | 19. Februar 2015 J | 184.386 | 0 | 0 | $0 |
| Celgene European Investment Co LLC | 10%-Eigentümer | 16. Dezember 2014 P | 1.231.778 | 0 | 0 | $0 |
| Sarah Gheuens | — | 4. August 2026 S | 54.645 | 0 | 2 | $-1.064.903 |
| Jay T. Backstrom | — | 8. Juli 2026 M | 1.447 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC | 5. April 2021 | — | Erste Einreichung | — | SEC |
| CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 Einreichungen | 14. November 2019 | — | Erste Einreichung | Kapitalstruktur | SEC |
| CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 Einreichungen | 17. Dezember 2014 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 57 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,64% | 34.703 NS | 30. April 2026 | N-PORT |
| SBIO · ALPS ETF Trust | 1,10% | 60.392 NS | 31. Mai 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 0,77% | 43.269 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,60% | 110.585 NS | 30. April 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,54% | 3.805 SH | 8. August 2026 | Täglich |
| AGNG · Global X Funds | 0,28% | 7.695 NS | 31. Mai 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,27% | 101.599 NS | 30. April 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,19% | 17.290 SH | 8. August 2026 | Täglich |
| IBB · iShares Trust | 0,14% | 408.719 SH | 8. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,13% | 3.239 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,13% | 48.730 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,13% | 113.617 SH | 8. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,12% | 109.727 NS | 31. Mai 2026 | N-PORT |
| IWN · iShares Trust | 0,11% | 515.162 SH | 8. August 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,09% | 40.934 NS | 30. April 2026 | N-PORT |
| BIB · ProShares Trust | 0,09% | 2.166 NS | 31. Mai 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 22.172 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 340.226 SH | 8. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,06% | 788.655 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,06% | 1.508.427 SH | 8. August 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,06% | 9.472 NS | 30. April 2026 | N-PORT |
| ESML · iShares Trust | 0,05% | 48.207 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,05% | 24.449 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,04% | 2.658 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 193.306 NS | 30. April 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 280.734 NS | 31. Mai 2026 | N-PORT |
| ISCG · iShares Trust | 0,03% | 10.195 SH | 8. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,03% | 1.364.364 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 167.169 SH | 8. August 2026 | Täglich |
| ISCB · iShares Trust | 0,03% | 2.463 SH | 8. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 25.231 NS | 30. April 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 2.079 NS | 31. Mai 2026 | N-PORT |
| ISCV · iShares Trust | 0,02% | 5.020 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 683.802 SH | 8. August 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,02% | 2.762 NS | 30. April 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 2.105 NS | 31. Mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.903 NS | 31. Mai 2026 | N-PORT |
| WSML · iShares Trust | 0,02% | 3.329 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 3.639 SH | 8. August 2026 | Täglich |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 2.328 NS | 31. Mai 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 136.570 NS | 30. April 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 8.867 NS | 30. April 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 53 NS | 31. Mai 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 25.095 NS | 31. Mai 2026 | N-PORT |
| IWO · iShares Trust | 0,01% | 30.958 SH | 8. August 2026 | Täglich |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,01% | 1.068 NS | 31. Mai 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 4.329 NS | 30. April 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 17.627 NS | 30. April 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 19.324 NS | 30. April 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 16.536 SH | 8. August 2026 | Täglich |